The Fort Worth Press - Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026

USD -
AED 3.672496
AFN 63.999637
ALL 81.031648
AMD 363.340421
ANG 1.790365
AOA 918.00039
ARS 1524.754198
AUD 1.42291
AWG 1.8
AZN 1.705597
BAM 1.7198
BBD 2.014334
BDT 123.134148
BGN 1.683441
BHD 0.376974
BIF 2996.596875
BMD 1
BND 1.278343
BOB 12.245759
BRL 5.213957
BSD 1.000132
BTN 95.938305
BWP 13.673816
BYN 3.027326
BYR 19600
BZD 2.011326
CAD 1.41705
CDF 2340.000016
CHF 0.831345
CLF 0.024498
CLP 967.330009
CNY 6.71325
CNH 6.71147
COP 3369.37
CRC 454.20569
CUC 1
CUP 24.002462
CVE 96.96141
CZK 21.428982
DJF 177.720211
DKK 6.57103
DOP 59.542287
DZD 133.831434
EGP 52.098498
ERN 15
ETB 162.972098
EUR 0.87899
FJD 2.2357
FKP 0.754816
GBP 0.753755
GEL 2.615005
GGP 0.754816
GHS 11.635494
GIP 0.754816
GMD 73.502842
GNF 8795.170658
GTQ 7.637958
GYD 209.257745
HKD 7.845065
HNL 26.846287
HRK 6.623098
HTG 130.885748
HUF 322.531034
IDR 18028
ILS 3.079601
IMP 0.754816
INR 95.93595
IQD 1310.042516
IRR 1374837.501412
ISK 120.430169
JEP 0.754816
JMD 158.315197
JOD 0.708997
JPY 157.244022
KES 129.729755
KGS 87.448502
KHR 4059.056814
KMF 433.000183
KPW 900.000318
KRW 1359.710329
KWD 0.30877
KYD 0.833443
KZT 439.793707
LAK 22439.127338
LBP 89556.106612
LKR 331.022111
LRD 172.008688
LSL 16.434096
LTL 2.95274
LVL 0.60489
LYD 6.397263
MAD 9.630717
MDL 17.680991
MGA 4387.052523
MKD 54.140561
MMK 2099.83552
MNT 3596.071123
MOP 8.080829
MRU 40.062785
MUR 47.469788
MVR 15.449932
MWK 1734.1564
MXN 17.85501
MYR 4.081702
MZN 63.909937
NAD 16.434096
NGN 1327.039625
NIO 36.800429
NOK 9.53582
NPR 153.505837
NZD 1.762425
OMR 0.384496
PAB 1.000079
PEN 3.398334
PGK 4.52425
PHP 62.465498
PKR 277.095071
PLN 3.839965
PYG 5873.947548
QAR 3.645277
RON 4.639494
RSD 103.307008
RUB 84.497761
RWF 1476.596231
SAR 3.755913
SBD 8.000512
SCR 13.873396
SDG 601.497925
SEK 9.94721
SGD 1.276995
SHP 0.755002
SLE 24.650298
SLL 20969.491881
SOS 571.60445
SRD 37.686023
STD 20697.981008
STN 21.545091
SVC 8.750324
SYP 13002.000254
SZL 16.429972
THB 33.563002
TJS 9.225649
TMT 3.51
TND 2.961507
TOP 2.40776
TRY 48.980798
TTD 6.787754
TWD 31.767976
TZS 2635.00303
UAH 44.876871
UGX 3914.861437
UYU 40.089518
UZS 11815.811573
VES 852.43145
VND 25974.5
VUV 117.801098
WST 2.745718
XAF 576.579692
XAG 0.01632
XAU 0.000241767514
XCD 2.70255
XCG 1.802386
XDR 0.707052
XOF 576.579692
XPF 104.870231
YER 236.649809
ZAR 16.393875
ZMK 9001.204285
ZMW 19.476614
ZWL 321.999592
SSP 5712.591902
MXV 2.022034
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026
Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026

Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026

Beverly Hills spine surgeon and principal investigator will present pooled clinical outcomes following recent FDA approval of motion-preserving cervical disc technology

Text size:

BEVERLY HILLS, CA / ACCESS Newswire / April 2, 2026 / Following the recent FDA Premarket Approval (PMA) of the Synergy Disc®, Todd H. Lanman, MD, a pioneer in motion-preserving spine surgery, will present the first full results from the U.S. Investigational Device Exemption (IDE) clinical trial at the International Society for the Advancement of Spine Surgery (ISASS) 2026 Annual Conference in Miami Beach, April 9-11. Dr. Lanman served as a principal investigator in the multicenter U.S. IDE study evaluating the motion-preserving cervical artificial disc, developed by Synergy Spine Solutions, for the treatment of single-level degenerative disc disease from C3-C7.

The Synergy Disc received FDA approval after demonstrating superiority to anterior cervical discectomy and fusion (ACDF) on the study's primary endpoint of composite clinical success at 24 months. In the IDE trial, the device achieved an 87.1% composite clinical success rate, significantly higher than the fusion control group.

Additional key findings included:

91.7% of patients achieved clinically meaningful improvement on the Neck Disability Index at two years compared with 75.2% in the fusion group

Lower mean neck pain scores in the Synergy Disc group (15.6 vs. 30.2 in the fusion cohort)

Lower worst arm pain scores (15.0 vs. 32.2)

Improved segmental alignment, with disc angle increasing from 2.6 degrees pre-operatively to 6.5 degrees at 24 months

Higher patient satisfaction, reported by 84.5% of Synergy Disc patients versus 61.6% of fusion patients

"Artificial disc replacement continues to evolve rapidly, and these IDE results tell a clear story - meaningful reductions in neck and arm pain, better function, and higher patient satisfaction over fusion," said Dr. Lanman. "For patients, that is just not a statistic. That is the ability to return to an active, unrestricted life. That is what motion preservation is ultimately about."

The Synergy device incorporates a lordotic polyethylene core engineered to preserve motion while improving spinal alignment, a design intended to reduce the risk of postoperative kyphosis and maintain physiologic cervical curvature.

Dr. Lanman's presentation at ISASS will provide spine surgeons with a detailed review of the IDE trial methodology, clinical outcomes, and implications for the future of cervical motion-preserving surgery.

The International Society for the Advancement of Spine Surgery (ISASS) Annual Conference is one of the premier scientific meetings dedicated to spine innovation and motion-preservation technologies. The 2026 meeting will bring together leading spine surgeons, researchers, and industry innovators to discuss emerging technologies and advances in spinal care.

About Dr. Todd H. Lanman

Todd Lanman, MD has over three decades of experience as a spinal neurosurgeon and has spent the last 25 years practicing spine surgery in Beverly Hills. In addition to being a world-renowned spinal surgeon, Dr. Lanman has also had 11 spinal surgeries including spinal fusions and artificial disc replacements. Because of these experiences as surgeon and as patient, Dr. Lanman brings a unique perspective to his surgical practice.

About Lanman Spinal Neurosurgery

Lanman Spinal Neurosurgery is committed to improving patients' quality of life by relieving pain and restoring spinal motion. The Beverly Hills practice has been at the leading edge of spine health for the past quarter of a century. Lanman Spinal Neurosurgery has and continues to pioneer artificial disc replacement and fusion revision surgeries to help neck and back pain sufferers live their best lives.

About Synergy Spine Solutions

Synergy Spine Solutions is a medical device company focused on improving the quality of life for patients undergoing spine surgery. The company develops motion-preserving technologies designed to treat degenerative disc disease while supporting the spine's natural curvature. Its flagship product, the FDA-approved Synergy Disc®, features a built-in 6-degree lordotic core designed to not only preserve motion but also improve sagittal alignment.

Media Contact:

Brandi Kamenar
Brandi Kamenar Brand Management
BrandiKamenar.com
Email: [email protected]
Phone: (310) 734-6180

SOURCE: Lanman Spinal Neurosurgery



View the original press release on ACCESS Newswire

P.Grant--TFWP